Skye Bioscience, Inc. (SKYE) financial statements (2022 and earlier)
Company profile
| Business Address |
11250 EL CAMINO REAL, SUITE 100 SAN DIEGO, CA 92130 |
| State of Incorp. | NV |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in thousands)
| 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 8,983 | 2,469 | 1,830 | 1,853 | 260 | 65 | 3,221 | ||
| Cash and cash equivalents | 8,983 | 2,469 | 1,830 | 1,853 | 260 | 65 | 3,221 | ||
| Restricted cash and investments | 5 | 5 | 5 | 5 | 4 | 38 | 38 | ||
| Receivables | 13 | ||||||||
| Prepaid expense | 554 | 190 | 153 | 93 | 291 | 170 | 159 | ||
| Other current assets | 57 | 0 | 8 | 3 | 7 | 36 | |||
| Total current assets: | 9,612 | 2,664 | 1,995 | 1,954 | 556 | 279 | 3,454 | ||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 147 | ✕ | ✕ | ✕ | ✕ | ||||
| Property, plant and equipment | 88 | 7 | 2 | 3 | 1 | 10 | 13 | ||
| Other noncurrent assets | 8 | 34 | 44 | ||||||
| Total noncurrent assets: | 243 | 7 | 2 | 3 | 1 | 44 | 57 | ||
| TOTAL ASSETS: | 9,855 | 2,672 | 1,997 | 1,957 | 557 | 323 | 3,511 | ||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 1,242 | 364 | 130 | 200 | 299 | 541 | 400 | ||
| Accounts payable | 898 | 364 | 130 | 16 | 101 | 275 | 125 | ||
| Accrued liabilities | 118 | 144 | 99 | 229 | |||||
| Employee-related liabilities | 344 | 66 | 55 | 167 | 46 | ||||
| Debt | 1,975 | 64 | 235 | ||||||
| Derivative instruments and hedges, liabilities | 60 | 39 | 411 | 15,739 | |||||
| Due to related parties | 2 | 17 | 10 | ||||||
| Deferred revenue and credits | ✕ | ✕ | ✕ | ✕ | 2 | ||||
| Other liabilities | 376 | 259 | 420 | ||||||
| Other undisclosed current liabilities | 257 | 44 | 272 | 119 | 182 | ||||
| Total current liabilities: | 3,912 | 787 | 971 | 15,939 | 806 | 662 | 582 | ||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 79 | 1,434 | 387 | 1,361 | |||||
| Long-term debt, excluding current maturities | 1,434 | 387 | 1,361 | ||||||
| Operating lease, liability | 79 | ✕ | ✕ | ✕ | ✕ | ||||
| Liabilities, other than long-term debt | 91 | 219 | 551 | 1,112 | 2,458 | ||||
| Deferred revenue and credits | ✕ | ✕ | ✕ | ✕ | 3 | ||||
| Derivative instruments and hedges, liabilities | 91 | 219 | 551 | 1,112 | 2,455 | ||||
| Other undisclosed noncurrent liabilities | (79) | ||||||||
| Total noncurrent liabilities: | 79 | 1,434 | 478 | 1,580 | 551 | 1,112 | 2,458 | ||
| Total liabilities: | 3,991 | 2,221 | 1,449 | 17,519 | 1,357 | 1,774 | 3,040 | ||
| Stockholders' equity | |||||||||
| Stockholders' equity attributable to parent | 5,864 | 451 | 548 | (15,562) | (3,570) | (2,914) | (892) | ||
| Common stock | 476 | 288 | 183 | 134 | 34 | 22 | 20 | ||
| Additional paid in capital | 52,644 | 38,897 | 32,538 | 16,231 | 9,445 | 7,163 | 6,087 | ||
| Accumulated deficit | (47,256) | (38,734) | (32,173) | (33,225) | (14,031) | (10,937) | (7,758) | ||
| Warrants and rights outstanding | 1,298 | 983 | 838 | 759 | |||||
| Other undisclosed stockholders' equity | 2,769 | 1,463 | 1,363 | ||||||
| Total stockholders' equity: | 5,864 | 451 | 548 | (15,562) | (800) | (1,451) | 471 | ||
| TOTAL LIABILITIES AND EQUITY: | 9,855 | 2,672 | 1,997 | 1,957 | 557 | 323 | 3,511 | ||
Income statement (P&L) ($ in thousands)
| 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | ||
|---|---|---|---|---|---|---|---|---|
| Operating expenses | (7,848) | (6,289) | (6,633) | (4,693) | (3,859) | (4,471) | (4,317) | |
| Operating loss: | (7,848) | (6,289) | (6,633) | (4,693) | (3,859) | (4,471) | (4,317) | |
| Nonoperating income (expense) | (672) | (270) | 7,686 | 0 | ||||
| Investment income, nonoperating | 0 | 0 | 0 | 0 | ||||
| Interest and debt expense | 118 | (706) | (725) | (685) | (1) | (52) | (585) | |
| Other undisclosed income (loss) from continuing operations before equity method investments, income taxes | 706 | 725 | (13,815) | 767 | ||||
| Income (loss) from continuing operations before equity method investments, income taxes: | (8,402) | (6,559) | 1,053 | (19,193) | (3,093) | (4,522) | (4,902) | |
| Other undisclosed income (loss) from continuing operations before income taxes | (118) | 1,346 | 63 | |||||
| Income (loss) from continuing operations before income taxes: | (8,520) | (6,559) | 1,053 | (19,193) | (3,093) | (3,176) | (4,839) | |
| Income tax expense | (2) | (2) | (2) | (2) | (2) | (2) | (2) | |
| Net income (loss) attributable to parent: | (8,522) | (6,561) | 1,052 | (19,194) | (3,094) | (3,178) | (4,841) | |
| Preferred stock dividends and other adjustments | (1,044) | (325) | ||||||
| Net income (loss) available to common stockholders, diluted: | (8,522) | (6,561) | 1,052 | (19,194) | (4,138) | (3,503) | (4,841) | |
Comprehensive Income ($ in thousands)
| 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | (8,522) | (6,561) | 1,052 | (19,194) | (3,094) | (3,178) | (4,841) | |
| Comprehensive income (loss), net of tax, attributable to parent: | (8,522) | (6,561) | 1,052 | (19,194) | (3,094) | (3,178) | (4,841) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.